1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. France >
  5. HiFiBiO Therapeutics Acquires H-Immune Therapeutics

M&A Deal Summary

HiFiBiO Therapeutics Acquires H-Immune Therapeutics

On October 15, 2018, HiFiBiO Therapeutics acquired life science company H-Immune Therapeutics

Acquisition Highlights
  • This is HiFiBiO Therapeutics’ 1st transaction in the Life Science sector.
  • This is HiFiBiO Therapeutics’ 1st transaction in France.

M&A Deal Summary
Date 2018-10-15
Target H-Immune Therapeutics
Sector Life Science
Buyer(s) HiFiBiO Therapeutics
Deal Type Add-on Acquisition

Target

H-Immune Therapeutics

Paris, France
H-Immune Therapeutics is an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

HiFiBiO Therapeutics

Paris, France
Category Company
Sector Life Science
DESCRIPTION

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. HiFiBiO Therapeutics is based in Paris, France.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: France M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal